Use of rapamycin derivatives in vasculopathies and xenotransplantation

Abstract

Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.

1 . A method for inhibiting or treating vascular surgery induced neointimal proliferation and thickening and/or restenosis and/or vascular occlusion comprising administering to a subject in need thereof an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin, wherein said method excludes co-administering one or more active pharmaceutical agents in addition to the effective amount of 40-O-(2-hydroxy)ethyl-rapamycin. 
     
     
         2 . A method according to  claim 1  for inhibiting or treating neointimal proliferation and thickening. 
     
     
         3 . A method according to  claim 1  for inhibiting or treating restenosis and/or vascular occlusion. 
     
     
         4 . A method according to  claim 1  for inhibiting or treating vascular occlusion. 
     
     
         5 . A method according to  claim 1 , wherein the vascular surgery is angioplasty. 
     
     
         6 . A method for inhibiting vascular surgery induced neointimal proliferation and thickening and/or restenosis and/or vascular occlusion comprising administering to a subject in need thereof an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin, wherein said method excludes co-administering one or more active pharmaceutical agents in addition to the effective amount of 40-O-(2-hydroxy)ethyl-rapamycin. 
     
     
         7 . A method according to  claim 6  for inhibiting neointimal proliferation and thickening. 
     
     
         8 . A method according to  claim 6  for inhibiting restenosis and/or vascular occlusion. 
     
     
         9 . A method according to  claim 6  for inhibiting vascular occlusion. 
     
     
         10 . A method according to  claim 6 , wherein the vascular surgery is angioplasty. 
     
     
         11 . A method for treating vascular surgery induced neointimal proliferation and thickening and/or restenosis and/or vascular occlusion comprising administering to a subject in need thereof an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin, wherein said method excludes co-administering one or more active pharmaceutical agents in addition to the effective amount of 40-O-(2-hydroxy)ethyl-rapamycin. 
     
     
         12 . A method according to  claim 11  for treating neointimal proliferation and thickening. 
     
     
         13 . A method according to  claim 11  for treating restenosis and/or vascular occlusion. 
     
     
         14 . A method according to  claim 11  for treating vascular occlusion. 
     
     
         15 . A method according to  claim 11 , wherein the vascular surgery is angioplasty.